India to United Kingdom: Amiodarone Export Trade Route

To import Amiodarone formulations into the UK, the following approvals and registrations are necessary:

1. Marketing Authorisation (MA): Each medicinal product must possess a valid UK Marketing Authorisation, confirming its safety, quality, and efficacy. The application should be submitted in the Common Technical Document (CTD) or electronic CTD (eCTD) format. Approval timelines vary but typically range from 12 to 18 months.

2. Wholesale Dealer's Licence (WDL): Importers must hold a WDL with an import authorisation, commonly referred to as WDL(H). This licence ensures compliance with Good Distribution Practice (GDP) standards and requires demonstration of adequate premises, qualified personnel, and robust quality management systems.

3. Manufacturing and Importation Authorisation (MIA): If the importer is involved in any manufacturing activities, including repackaging or relabeling, an MIA is required. This authorisation mandates compliance with Good Manufacturing Practice (GMP) standards.

4. GMP Inspection for Indian Manufacturing Facilities: The MHRA conducts GMP inspections of overseas manufacturing sites to ensure compliance with UK standards. Indian facilities producing Amiodarone formulations intended for the UK market must undergo and pass these inspections.

Indian exporters of Amiodarone formulations must adhere to the following GMP certifications and standards:

1. MHRA GMP Certification: Manufacturing facilities must obtain GMP certification from the MHRA, confirming compliance with UK GMP standards. Recent inspections include:

• Intas Pharmaceuticals Limited, Dehradun: Inspected on February 1, 2024.

• Sun Pharmaceutical Industries Limited, Dadra: Inspected on January 22, 2024.

• Cadila Pharmaceuticals Limited, Ahmedabad: Inspected on December 11, 2023.

2. Compliance with Revised Schedule M: As of January 6, 2024, India's Ministry of Health revised Schedule M to align with global GMP standards, introducing requirements such as Pharmaceutical Quality System (PQS), Quality Risk Management (QRM), and Product Quality Review (PQR). Indian manufacturers must comply with these updated standards to ensure product quality and facilitate exports to the UK.

Several regulatory changes between 2024 and 2026 have impacted Indian pharmaceutical exports to the UK:

1. Implementation of the Windsor Framework (Effective January 1, 2025): The MHRA introduced new guidance for manufacturers and wholesalers, including labeling, packaging, and importing requirements for human medicines. Notably, medicines must display a 'UK Only' label starting January 1, 2025.

2. Revised Schedule M in India (January 6, 2024): India's Health Ministry updated GMP regulations to align with global standards, introducing new categories of drugs and emphasizing quality management systems. Compliance with these revisions is essential for Indian manufacturers exporting to the UK.

Staying informed about these regulatory developments is crucial for Indian exporters to maintain compliance and ensure uninterrupted access to the UK market.

Amiodarone is a critical antiarrhythmic medication used extensively in the United Kingdom for managing various cardiac arrhythmias. The demand for Amiodarone formulations is driven by the country's aging population, with a significant proportion over 65 years old, and the prevalence of cardiovascular diseases. In the fiscal year 2024-2025, the National Health Service (NHS) reported a consistent prescription rate for Amiodarone, reflecting its essential role in cardiac care. While the UK has domestic pharmaceutical manufacturing capabilities, it relies on imports to meet the full demand for Amiodarone formulations. India is a notable supplier, contributing to the UK's pharmaceutical imports.

Pharmaceutical products under HS code 30049099, including Amiodarone formulations, are subject to a 0% Most-Favored-Nation (MFN) import duty rate in the United Kingdom. This exemption aligns with the UK's policy to facilitate access to essential medicines. Additionally, there are no anti-dumping duties imposed on these pharmaceutical imports. The UK has not established a Free Trade Agreement (FTA) with India that specifically affects pharmaceutical tariffs; however, the existing 0% duty rate ensures that imports from India are not subject to additional tariffs.

India is a significant exporter of Amiodarone formulations to the United Kingdom, accounting for approximately 0.5% of India's total Amiodarone formulation exports, valued at $74.6 million. The primary Indian exporters include MEDREICH LIMITED and INTAS PHARMACEUTICALS LIMITED. Other major countries supplying Amiodarone formulations to the UK include Germany and the United States. India's competitive pricing, coupled with its robust pharmaceutical manufacturing infrastructure, positions it favorably against competitors. The cost-effectiveness of Indian pharmaceutical products, without compromising quality, makes them attractive to UK importers seeking reliable and affordable sources for essential medications.

India is a leading global producer of generic pharmaceuticals, with a significant share in the manufacturing of finished dosage forms containing Amiodarone. The country's pharmaceutical industry benefits from a cost-effective production structure, enabling competitive pricing for formulations such as tablets, capsules, and syrups. As of November 2024, India had 396 facilities registered with the U.S. FDA, encompassing both Active Pharmaceutical Ingredients (API) and Finished Dosage Forms (FDF) manufacturing. This extensive network of WHO-GMP and FDA-approved facilities underscores India's capability to produce high-quality Amiodarone formulations that meet stringent international standards.

When comparing Amiodarone formulation exports, India offers a favorable balance of cost and quality. The National Pharmaceutical Pricing Authority (NPPA) of India set the ceiling price for Amiodarone tablets at ₹6.93 per 100 mg tablet and ₹11.67 per 200 mg tablet as of April 2014. While this data is from 2014, it reflects India's commitment to affordable pricing. In contrast, European manufacturers often have higher production costs, leading to more expensive branded generics. China, while competitive in pricing, has faced quality perception challenges and regulatory scrutiny. Indian manufacturers have a strong track record of regulatory compliance, with numerous facilities approved by international bodies, ensuring consistent quality and supply reliability.

The India-United Kingdom supply chain for Amiodarone formulations is robust, supported by India's substantial manufacturing capacity and advanced packaging and cold chain logistics. Indian pharmaceutical companies have demonstrated a strong regulatory compliance record, with facilities regularly inspected and approved by authorities such as the U.S. FDA and the UK's MHRA. For instance, in May 2024, the U.S. FDA completed a routine GMP inspection at Dr. Reddy's Laboratories' formulations manufacturing facilities in Visakhapatnam, issuing a Form 483 with two observations, which were promptly addressed. This proactive approach to compliance minimizes the risk of supply disruptions. Additionally, leading Indian manufacturers have been expanding their capacities to meet growing global demand, ensuring a reliable supply of Amiodarone formulations.

• Implement a Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Amiodarone formulations.

• Negotiate Favorable Minimum Order Quantities (MOQs): While MOQs can vary, collaborating closely with suppliers can help establish quantities that align with your demand forecasts and storage capabilities.

• Establish Clear Payment Terms: Common payment terms in India-United Kingdom pharmaceutical trade include letters of credit (LC) and advance payments. Clearly define terms to ensure smooth financial transactions.

• Conduct Comprehensive Supplier Qualification: Evaluate potential suppliers based on their regulatory compliance history, manufacturing capabilities, quality assurance processes, and financial stability to ensure they meet your standards.

• Monitor Regulatory Compliance: Regularly review the regulatory status of your suppliers' facilities to ensure ongoing compliance with international standards, thereby maintaining the integrity of your supply chain.

By adhering to this comprehensive approach, United Kingdom companies can ensure the selection of reliable Indian suppliers for Amiodarone formulations, thereby safeguarding product quality and regulatory compliance.